vs
Side-by-side financial comparison of Civeo Corp (CVEO) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
Civeo Corp is the larger business by last-quarter revenue ($161.6M vs $86.8M, roughly 1.9× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 7.1%). Civeo Corp produced more free cash flow last quarter ($14.5M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -1.4%).
The Civeo Corporation is an American accommodation services multinational corporation. It is a spin-off of Oil States International. It is a public company listed on the New York Stock Exchange.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CVEO vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $161.6M | $86.8M |
| Net Profit | $-6.5M | — |
| Gross Margin | 22.7% | 67.4% |
| Operating Margin | -0.1% | -84.7% |
| Net Margin | -4.0% | — |
| Revenue YoY | 7.1% | 17.7% |
| Net Profit YoY | 58.1% | — |
| EPS (diluted) | $-0.58 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $161.6M | $86.8M | ||
| Q3 25 | $170.5M | $67.5M | ||
| Q2 25 | $162.7M | $60.0M | ||
| Q1 25 | $144.0M | $49.3M | ||
| Q4 24 | $151.0M | $73.7M | ||
| Q3 24 | $176.3M | $58.6M | ||
| Q2 24 | $188.7M | $31.1M | ||
| Q1 24 | $166.1M | $715.0K |
| Q4 25 | $-6.5M | — | ||
| Q3 25 | $-455.0K | $-91.3M | ||
| Q2 25 | $-3.3M | $-111.7M | ||
| Q1 25 | $-9.8M | $-116.2M | ||
| Q4 24 | $-15.4M | — | ||
| Q3 24 | $-5.1M | $-83.5M | ||
| Q2 24 | $8.2M | $-97.1M | ||
| Q1 24 | $-5.1M | $-113.0M |
| Q4 25 | 22.7% | 67.4% | ||
| Q3 25 | 25.7% | 43.0% | ||
| Q2 25 | 25.3% | 5.5% | ||
| Q1 25 | 20.4% | -0.8% | ||
| Q4 24 | 18.6% | 68.7% | ||
| Q3 24 | 21.4% | 46.2% | ||
| Q2 24 | 25.4% | -0.8% | ||
| Q1 24 | 21.5% | — |
| Q4 25 | -0.1% | -84.7% | ||
| Q3 25 | 4.1% | -140.7% | ||
| Q2 25 | 1.7% | -189.8% | ||
| Q1 25 | -3.8% | -245.8% | ||
| Q4 24 | -6.7% | -117.5% | ||
| Q3 24 | 0.0% | -152.1% | ||
| Q2 24 | 6.9% | -327.6% | ||
| Q1 24 | -1.1% | -16464.6% |
| Q4 25 | -4.0% | — | ||
| Q3 25 | -0.3% | -135.3% | ||
| Q2 25 | -2.0% | -186.2% | ||
| Q1 25 | -6.8% | -235.5% | ||
| Q4 24 | -10.2% | — | ||
| Q3 24 | -2.9% | -142.7% | ||
| Q2 24 | 4.4% | -312.2% | ||
| Q1 24 | -3.1% | -15800.8% |
| Q4 25 | $-0.58 | — | ||
| Q3 25 | $-0.04 | — | ||
| Q2 25 | $-0.25 | $-0.33 | ||
| Q1 25 | $-0.72 | $-0.36 | ||
| Q4 24 | $-1.04 | $-0.24 | ||
| Q3 24 | $-0.36 | $-0.28 | ||
| Q2 24 | $0.56 | $-0.34 | ||
| Q1 24 | $-0.35 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.4M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $174.4M | $698.6M |
| Total Assets | $477.4M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $297.0M | ||
| Q3 25 | $12.0M | $300.8M | ||
| Q2 25 | $14.6M | $301.2M | ||
| Q1 25 | $28.4M | $359.7M | ||
| Q4 24 | $5.2M | $323.8M | ||
| Q3 24 | $17.9M | $397.5M | ||
| Q2 24 | $7.4M | $412.5M | ||
| Q1 24 | $16.8M | $356.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $43.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $174.4M | $698.6M | ||
| Q3 25 | $182.5M | $702.3M | ||
| Q2 25 | $209.4M | $698.5M | ||
| Q1 25 | $220.7M | $767.9M | ||
| Q4 24 | $236.4M | $710.4M | ||
| Q3 24 | $282.2M | $773.5M | ||
| Q2 24 | $297.4M | $768.5M | ||
| Q1 24 | $297.4M | $680.0M |
| Q4 25 | $477.4M | $913.2M | ||
| Q3 25 | $491.1M | $904.9M | ||
| Q2 25 | $508.8M | $907.4M | ||
| Q1 25 | $423.8M | $966.7M | ||
| Q4 24 | $405.1M | $910.4M | ||
| Q3 24 | $477.6M | $991.1M | ||
| Q2 24 | $483.2M | $964.3M | ||
| Q1 24 | $513.1M | $869.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.3M | $-52.6M |
| Free Cash FlowOCF − Capex | $14.5M | $-61.9M |
| FCF MarginFCF / Revenue | 8.9% | -71.3% |
| Capex IntensityCapex / Revenue | 3.0% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.3M | $-52.6M | ||
| Q3 25 | $13.8M | $-78.7M | ||
| Q2 25 | $-2.3M | $-67.4M | ||
| Q1 25 | $-8.4M | $-103.7M | ||
| Q4 24 | $9.5M | $-73.3M | ||
| Q3 24 | $35.7M | $-59.0M | ||
| Q2 24 | $32.4M | $-98.4M | ||
| Q1 24 | $6.0M | $-122.3M |
| Q4 25 | $14.5M | $-61.9M | ||
| Q3 25 | $8.2M | $-89.5M | ||
| Q2 25 | $-6.8M | $-74.9M | ||
| Q1 25 | $-13.7M | $-109.9M | ||
| Q4 24 | $1.8M | $-77.5M | ||
| Q3 24 | $28.2M | $-61.3M | ||
| Q2 24 | $27.0M | $-98.9M | ||
| Q1 24 | $372.0K | $-126.5M |
| Q4 25 | 8.9% | -71.3% | ||
| Q3 25 | 4.8% | -132.7% | ||
| Q2 25 | -4.2% | -124.9% | ||
| Q1 25 | -9.5% | -222.8% | ||
| Q4 24 | 1.2% | -105.1% | ||
| Q3 24 | 16.0% | -104.6% | ||
| Q2 24 | 14.3% | -317.9% | ||
| Q1 24 | 0.2% | -17685.3% |
| Q4 25 | 3.0% | 10.7% | ||
| Q3 25 | 3.3% | 16.1% | ||
| Q2 25 | 2.8% | 12.4% | ||
| Q1 25 | 3.7% | 12.6% | ||
| Q4 24 | 5.1% | 5.7% | ||
| Q3 24 | 4.2% | 3.9% | ||
| Q2 24 | 2.8% | 1.4% | ||
| Q1 24 | 3.4% | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.93× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVEO
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
